Astroglial Connexins Inactivation Increases Relapse of Depressive-like Phenotype after Antidepressant Withdrawal

• Published in: International journal of molecular sciences 2022-11, Vol.23 (21), p.13227
• Main Authors: Portal, Benjamin, Vasile, Flora, Zapata, Jonathan, Lejards, Camille, Ait Tayeb, Abd El Kader, Colle, Romain, Verstuyft, Céline, Corruble, Emmanuelle, Rouach, Nathalie, Guiard, Bruno P.
• Format: Article
• Language: English
• Subjects: Animals; antidepressant; Antidepressants; astrocytes; Brief Report; Connexins; Corticosterone; Drug withdrawal; Drugs; Human health and pathology; Hypotheses; Life Sciences; major depression; Mental depression; Mental disorders; monoamines; Neurobiology; Neurons and Cognition; Peptides; Pharmaceutical sciences; Pharmacology; Phenotypes; Psychiatrics and mental health; Synapses; Venlafaxine; Withdrawal
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232113227

Studies suggest that astrocytic connexins (Cx) have an important role in the regulation of high brain functions through their ability to establish fine-tuned communication with neurons within the tripartite synapse. In light of these properties, growing evidence suggests a role of Cx in psychiatric disorders such as major depression but also in the therapeutic activity of antidepressant drugs. However, the real impact of Cx on treatment response and the underlying neurobiological mechanisms remain yet to be clarified. On this ground, the present study was designed to evaluate the functional activity of Cx in a mouse model of depression based on chronic corticosterone exposure and to determine to which extent their pharmacological inactivation influences the antidepressant-like activity of venlafaxine (VENLA). On the one hand, our results indicate that depressed mice have impaired Cx-based gap-junction and hemichannel activities. On the other hand, while VENLA exerts robust antidepressant-like activity in depressed mice; this effect is abolished by the pharmacological inhibition of Cx with carbenoxolone (CBX). Interestingly, the combination of VENLA and CBX is also associated with a higher rate of relapse after treatment withdrawal. To our knowledge, this study is one of the first to develop a model of relapse, and our results reveal that Cx-mediated dynamic neuroglial interactions play a critical role in the efficacy of monoaminergic antidepressant drugs, thus providing new targets for the treatment of depression.